Supplements

MSM: methylsulfonylmethane, small knee-pain studies, mixed arthritis endpoints, a negative prevention trial, combination products, and food-safety boundaries

7 sources · Latest source check 2026-10-09 UTC

On this page

MSM is methylsulfonylmethane, a sulfur-containing substance sold as a supplement. Selected studies suggest modest improvements in some knee-pain or function measures. They do not establish universal arthritis treatment, cartilage restoration or prevention of pain during intensive training. A prevention trial in military trainees was negative.[4][2]

The tested questions differ

The tested questions differ
Term	Meaning
MSM	Methylsulfonylmethane, a sulfur-containing compound.[4]
WOMAC	An arthritis questionnaire with separate pain, stiffness and function measures.[2]
JKOM	Japanese Knee Osteoarthritis Measure, used in the 2023 mild-pain trial.[3]
Prevention	Avoiding a new problem, different from treating existing arthritis symptoms.[4]
GRAS notification	A food-use safety process with specified intended conditions.[7]

The 2006 pilot involved fifty adults with knee osteoarthritis

A randomized, double-blind, placebo-controlled trial followed fifty adults for twelve weeks. MSM improved WOMAC pain and physical function more than placebo, while stiffness and the aggregated symptom score did not significantly change. A daily-activities quality-of-life measure was favorable. The findings were selective rather than proof that every measured outcome improved.[1]

The pilot did not confirm long-term benefit or safety

The authors reported no major adverse events during the short intervention but explicitly stated that long-term benefit and safety could not be confirmed from the pilot. Sample size, follow-up, missing-data handling, sponsor roles and clinical importance need fuller assessment. This result cannot establish lifelong compatibility with medicines or every combination product.[1]

The 2023 study concerned healthy participants with mild knee pain

Eighty-eight Japanese participants were randomized equally to MSM or placebo for twelve weeks. The prespecified primary outcome was the total JKOM score at week twelve. The between-group comparison favored MSM, with P = 0.046. The population was described as healthy participants with mild knee pain; this is different from confirmed, advanced osteoarthritis.[3]

A questionnaire signal does not establish cartilage recovery

The trial also reported selected favorable health-condition questionnaire findings. These outcomes do not demonstrate cartilage regeneration or prevention of surgery. A P value close to a conventional threshold is not an effect size or a measure of how much benefit matters to participants. Complete multiplicity, precision, missing-data and sponsor-role appraisal remains pending.[3]

The military-training prevention study was negative

The 2017 trial enrolled 180 trainees aged eighteen to forty, comparing MSM with placebo for eight weeks. It found no significant improvements in the five knee-outcome subscales or six mood subscales at thirty or sixty days. Treating existing arthritis and preventing symptoms during high-impact training should not be regarded as interchangeable indications.[4]

RADIANT tested a mixture rather than MSM alone

The hand-osteoarthritis trial tested Boswellia, pine bark, MSM and curcumin together against placebo for twelve weeks. Its primary hand-pain comparison was nonsignificant. This is the same RADIANT study discussed in the Boswellia article. Its mixture cannot establish MSM’s independent contribution or be counted as an additional single-ingredient replication.[5]

Treatment discontinuations are part of the result

Five participants in the mixture group and four in the placebo group discontinued treatment because of adverse events. These small counts concern the mixture and do not identify the ingredient responsible or establish equal risk. The primary efficacy result and limited safety information should both remain visible.[5]

The FDA inventory describes a defined food-use notification

GRN 229 was filed in 2007 and closed in February 2008 with a no-questions response. It concerns specified meal-related foods, beverages and bars, with food-concentration limits. A 2017 entry records correspondence about a specification change. A current catalog date is not a new clinical trial or unlimited approval of therapeutic uses.[6]

A food concentration is not a personal supplement dose

The notice expresses limits in milligrams per kilogram of a food. That unit is different from milligrams per kilogram of a person’s body weight. The intended food categories and specifications define the notice’s scope. Full notice, response-letter and subsequent correspondence appraisal remain pending.[6]

No questions is a scoped regulatory response

FDA explains that its response concerns whether the notice supplies a basis for the notifier’s food-use safety determination. That process does not demonstrate arthritis efficacy, prevention during training or safety for every medicinal exposure and special population. The food-use question should be kept separate from the treatment question.[7]

The process does not replace condition-specific safety research

Food categories, manufacturing specifications and actual exposure matter. A favorable short symptom trial cannot establish a complete lifetime safety or medicine-interaction profile. Pregnancy, childhood, complex disease, product mixtures and uncommon harms require evidence beyond the studies summarized here. This page is an explanation rather than a personal MSM plan.[7]

Evidence & uncertainty

Different endpoints give different answers. The 2011 arthritis trial reported favorable function and total questionnaire scores, while its WOMAC pain and stiffness comparisons were nonsignificant. Its authors questioned the clinical importance of the small improvements. A positive measure should not be generalized to every symptom or purpose.[2]

Selected-source overview · Independent review pending

Published questions

Did the 2011 MSM trial significantly improve every WOMAC component?

Selected-source overview · Independent review pending. Read the evidence context.

Pain and stiffness comparisons were nonsignificant.[2]

Evidence behind this answer

Efficacy of methylsulfonylmethane supplementation on osteoarthritis of the knee
randomized trial · 2011
Original full abstract inspected; full methods, statistical reporting and trial-level appraisal pending · 2011 original full abstract: 49 adults, twelve weeks, mixed endpoints and incompletely reconciled interval/P-value reporting